Filtered By:
Specialty: Pharmaceuticals
This page shows you your search results in order of date. This is page number 7.
Order by Relevance | Date
Total 890 results found since Jan 2013.
Psychosocial Stress Tied to Higher Risk for Acute Stroke
THURSDAY, Dec. 15, 2022 -- Self-reported psychosocial stress is associated with an increased risk for stroke, according to a study published online Dec. 9 in JAMA Network Open.
Catriona Reddin, from National University of Ireland Galway, and...
Source: Drugs.com - Pharma News - December 15, 2022 Category: Pharmaceuticals Source Type: news
Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Helping defeat diabetes in Arizona
Today, 1 in 10 Arizonans — about 786,000 people — have diabetes, a disease that impacts the way the body turns food into energy. People living with diabetes are also more than twice as likely to have a stroke and more prone to suffering from depression. Nationally, it is the eighth leading cause of death, and the number -one cause of kidney failure, foot and lower leg amputation, and blindness in adults.*
At Blue Cross Blue Shield of Arizona (BCBSAZ), it’s our mission to inspire health and…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 1, 2022 Category: Pharmaceuticals Authors: Blue Cross Blue Shield of Arizona Source Type: news
IHD, Stroke Risk Up for Offspring Born to Moms With Preeclampsia
THURSDAY, Nov. 17, 2022 -- Offspring born to individuals with preeclampsia have an increased risk for ischemic heart disease (IHD) and stroke, according to a study published online Nov. 15 in JAMA Network Open.
Fen Yang, M.D., from the Karolinska...
Source: Drugs.com - Pharma News - November 17, 2022 Category: Pharmaceuticals Source Type: news
Brain Bleeds Up in Patients With COVID-19 Treated for Ischemic Stroke
THURSDAY, Nov. 10, 2022 -- Patients with acute ischemic stroke who also have COVID-19 have higher rates of intracranial bleeding complications and worse clinical outcomes following revascularization treatment than similar patients without COVID-19,...
Source: Drugs.com - Pharma News - November 10, 2022 Category: Pharmaceuticals Source Type: news
Late-Breaking Data from Pivotal Phase 3 PRECISION Study Demonstrates Significant and Sustained Effect of Aprocitentan on Lowering Blood Pressure for Patients with Difficult-to-Control Hypertension
RARITAN, NJ, November 7, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with Idorsia Ltd, today announced results from the Phase 3 PRECISION study, which found aprocitentan, an investigational, novel dual endothelin receptor antagonist (ERA), significantly reduced blood pressure (BP) and maintained the effect for up to 48 weeks when added to standardized combination background antihypertensive therapy in patients with difficult-to-control hypertension (sometimes referred to as resistant hypertension). These data were presented as a Late-Breaking Science presentation during the Amer...
Source: Johnson and Johnson - November 7, 2022 Category: Pharmaceuticals Source Type: news
Janssen ’s Save Legs. Change Lives.™ is Creating a More Equitable Future for Communities at Risk of PAD-Related Amputations
TITUSVILLE, NJ, November 4, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the first impact summary for its Save Legs. Change Lives.™ Spot Peripheral Artery Disease Now multi-year initiative, designed to create urgency and action around the hidden threat of peripheral artery disease (PAD)-related amputation. In its inaugural year, Save Legs. Change Lives.™ focused on reaching Black Americans, who are up to four times more likely than white Americans to have a PAD-related amputation.1 With this critical initiative, Janssen is focused on helping those at risk of PAD through more th...
Source: Johnson and Johnson - November 4, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Moderate-to-Heavy Drinking Linked to Stroke Risk in Young Adults
WEDNESDAY, Nov. 2, 2022 -- For young adults, moderate-to-heavy drinking is associated with an increased risk for stroke, according to a study published online Nov. 2 in Neurology.
Jae-wook Chung, M.D., from Seoul National University Hospital in...
Source: Drugs.com - Pharma News - November 2, 2022 Category: Pharmaceuticals Source Type: news
Benefit of Ticagrelor-Aspirin in Stroke Patients Tied to Renal Function
TUESDAY, Nov. 1, 2022 -- Among CYP2C19 loss-of-function allele carriers with minor stroke or transient ischemic attack, those with normal renal function rather than impaired renal function derive greater benefit from ticagrelor-aspirin versus...
Source: Drugs.com - Pharma News - November 1, 2022 Category: Pharmaceuticals Source Type: news
U.S. FDA Approves TECVAYLI ™ (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., October 25, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved TECVAYLI™ (teclistamab-cqyv) for the treatment of adult patients with relapsed or refractory multiple myeloma, who previously received four or more prior lines of therapy, including a proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody.1 TECVAYLI™ is a first-in-class, bispecific T-cell engager antibody that is administered as a subcutaneous treatment.1 This off-the-shelf (or ready to use) therapy uses innovative science to ac...
Source: Johnson and Johnson - October 25, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Apixaban Compared to Rivaroxaban for A-Fib and Valvular Heart Disease
WEDNESDAY, Oct. 19, 2022 -- For patients with atrial fibrillation (AF) and valvular heart disease (VHD), apixaban is associated with a reduced risk for ischemic stroke or systemic embolism and a reduced risk for bleeding compared with rivaroxaban,...
Source: Drugs.com - Pharma News - October 19, 2022 Category: Pharmaceuticals Source Type: news
Survey: Noncommunicable Diseases Still Underestimated, Only 59% View Diabetes As Very Harmful
Gallup also found that of those interviewed only 83% considered cancer, 72% considered heart disease and stroke, and 51% considered lung disease to be "very harmful. ”
Source: Forbes.com Healthcare News - October 17, 2022 Category: Pharmaceuticals Authors: Bruce Y. Lee, Senior Contributor Tags: Healthcare /healthcare Innovation /innovation Business /business Food & Drink /food-drink pharma Source Type: news
Endovascular Therapy Aids Outcome of Basilar-Artery Occlusion
THURSDAY, Oct. 13, 2022 -- For patients with basilar-artery occlusion, a greater percentage with good functional status at 90 days is seen with endovascular thrombectomy within 12 hours after stroke, or within six and 24 hours after stroke onset,...
Source: Drugs.com - Pharma News - October 13, 2022 Category: Pharmaceuticals Source Type: news
Functional Stroke Recovery Varies by Age, Sex, and Stroke Type
TUESDAY, Oct. 11, 2022 -- Following stroke, long-term recovery patterns in multifaceted functional domains differ by patient age, stroke severity, and stroke type, according to a study published online Sept. 23 in JAMA Network Open.
Seyoung Shin,...
Source: Drugs.com - Pharma News - October 11, 2022 Category: Pharmaceuticals Source Type: news
AI-Enabled Retinal Vasculometry May Help Assess Vascular Health
WEDNESDAY, Oct. 5, 2022 -- Artificial intelligence (AI)-enabled retinal vasculometry (RV) can help predict circulatory mortality, incident stroke, and myocardial infarction (MI), according to a study published online Oct. 4 in the British Journal of...
Source: Drugs.com - Pharma News - October 5, 2022 Category: Pharmaceuticals Source Type: news
